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Abstract The implementation of a variety of immunosup-
pressive therapies has made drug-associated progressive
multifocal leukoencephalopathy (PML) an increasingly
prevalent clinical entity. The purpose of this study was to
investigate its diagnostic characteristics and to determine
whether differences herein exist between the multiple scle-
rosis (MS), neoplasm, post-transplantation, and autoimmune
disease subgroups. Reports of possible, probable, and defi-
nite PML according to the current diagnostic criteria were
obtained by a systematic search of PubMed and the Dutch
pharmacovigilance database. Demographic, epidemiologic,
clinical, radiological, cerebrospinal fluid (CSF), and
histopathological features were extracted from each report
and differences were compared between the disease
categories. In the 326 identified reports, PML onset occur-
red on average 29.5 months after drug introduction, varying
from 14.2 to 37.8 months in the neoplasm and MS sub-
groups, respectively. The most common overall symptoms
were motor weakness (48.6 %), cognitive deficits (43.2 %),
dysarthria (26.3 %), and ataxia (24.1 %). The former two
also constituted the most prevalent manifestations in each
subgroup. Lesions were more often localized supratentori-
ally (87.7 %) than infratentorially (27.4 %), especially in the
frontal (64.1 %) and parietal lobes (46.6 %), and revealed
enhancement in 27.6 % of cases, particularly in the MS
(42.9 %) subgroup. Positive JC virus results in the first CSF
sample were obtained in 63.5 %, while conversion after one
or more negative outcomes occurred in 13.7 % of cases.
52.2 % of patients died, ranging from 12.0 to 83.3 % in the
MS and neoplasm subgroups, respectively. In conclusion,
despite the heterogeneous nature of the underlying diseases,
motor weakness and cognitive changes were the two most
common manifestations of drug-associated PML in all
subgroups. The frontal and parietal lobes invariably consti-
tuted the predilection sites of drug-related PML lesions.
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Introduction
Progressive multifocal leukoencephalopathy (PML) is a JC
virus (JCV) related demyelinating disorder of the central
nervous system that occurs almost exclusively in
immunocompromised patients [1]. It is characterized
histopathologically by a lytic infection of oligodendro-
cytes, astrocytes, and/or neurons in the white matter, cor-
tical gray matter, and/or gray-white matter junction giving
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rise to a plethora of clinical phenotypes [2]. Quintessential
radiological lesions are hyperintense on T2-weighted and
FLAIR images and hypointense on T1-weighted images. In
2013, diagnostic criteria have been established which
include clinical, imaging, laboratory, and histopathological
features. Prerequisite for a definite diagnosis of PML is
either the presence of characteristic pathoanatomic findings
in a biopsy specimen or a combination of the appropriate
clinical symptoms, radiological features, and the detection
of JCV DNA in cerebrospinal fluid (CSF) [3]. Cases that do
not fulfill these criteria might be classified as possible or
probable PML and may be missed in official statistics.
PML has traditionally been associated with an intrinsi-
cally compromised immune system. In the past few years, a
considerable number of immunosuppressive drugs has been
approved by the authorities and implemented into clinical
practice to broaden the therapeutic spectrum of a variety of
medical conditions [4–6]. Consequently, medication-asso-
ciated PML has become an increasingly prevalent clinical
entity, as reflected by an exponential increase in the
number of published cases (Fig. 1). Because of the fre-
quently poor prognosis of PML, it is of paramount
importance to establish this diagnosis at an early stage.
However, a comprehensive, quantitative analysis of the
clinical, radiological, and CSF features of drug-associated
PML and its subgroups, based on the underlying disease
categories, has never been conducted thus far. Neverthe-
less, for an early diagnosis it is crucial for clinicians across
various specialties to be aware of the preferential clinical
and radiological presentation and the potential differences
herein between the subgroups. In this study, we aimed to
address this urgent medical need for advances in knowl-
edge on drug-associated PML by outlining its specific
clinical, radiological, and CSF characteristics. A quantita-
tive assessment of the degree of association between any
particular drug and PML has been reported previously, and
therefore fell beyond the scope of this paper [7].
Methods
Inclusion of published reports
References were identified by means of a three-step
PubMed search conducted on August 30, 2015 (Fig. 2). To
obtain a first inventory of the drugs that might trigger PML
occurrence, the search terms ‘progressive multifocal
leukoencephalopathy’, ‘drug induced’, ‘chemically
induced’, ‘medication induced’, ‘adverse event’, ‘adverse
effect’, and ‘side effect’ were used in the ‘all fields’ menu
without limits of time. Second, combinations of ‘progres-
sive multifocal leukoencephalopathy’ and the names of
each of the individual drugs that had been identified in the
first step were applied to collect all reports of potentially
drug-associated PML. Finally, reference lists of all inclu-
ded articles were screened for any additional relevant
reports.
We included cases of possible, probable, and definite
PML according to the current American Academy of
Neurology criteria [3] that were published in English lan-
guage journals in case reports, case series, clinical trials,
editorials, letters, meta-analyses, and observational studies.
In addition, articles were included when they described a
simultaneous immune reconstitution inflammatory syn-
drome (IRIS), either occurring already during treatment
with or only after withdrawal of the causative drug. With
respect to the latter, IRIS was defined as deterioration of
neurologic deficits following drug removal, corroborated
by inflammatory changes on neuroimaging [8]. Articles
were excluded if an identical case had already been
described in a previous report, when PML was not related
to a drug, or if an alternative diagnosis was more likely,
e.g., posterior reversible encephalopathy syndrome (PRES)
associated with tacrolimus, cyclosporine, cisplatin, and
methotrexate. Finally, cases of medication-related granule
cell neuronopathy were excluded [9, 10]. When imaging
features played a pivotal role in the distinction between
‘possible PML’ and ‘not PML’, the decision of inclusion or
exclusion was made after analysis by an experienced
neuroradiologist with special expertise in the field of
inflammatory diseases of the central nervous system
(MPW).
Fig. 1 Number of published reports on drug-associated PML
throughout the years, as included in this paper
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Dutch pharmacovigilance database
In addition to the cases published in the literature, reports
on medication-associated PML were obtained by querying
the database of the Netherlands Pharmacovigilance Centre
Lareb. This database contains detailed accurately verified
information of adverse drug reactions reported by Dutch
healthcare professionals and manufacturers. Care was
taken to exclude duplicates that had already been included
in the literature search.
Fig. 2 Flowchart of the search strategy, selection, and inclusion of articles and reports from the Dutch pharmacovigilance database
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Data acquisition
The following data, when available, were extracted from
each report: study type, number of cases, age, sex, under-
lying disease, immunosuppressive agent(s), time elapsed
between drug introduction and either first symptoms or
asymptomatic radiological findings that could be attributed
to PML in retrospect, mortality rate (and time from first
symptoms to death), and clinical, radiological, CSF, and
histopathological features. When a combination of thera-
pies rather than a single pharmaceutical was presumed to
be responsible for the phenotype, the most likely con-
tributing drugs—based on mechanism of action, dose, and
duration of use—were noted up to a maximum of three.
The localization of PML lesions was determined by the
description provided by the authors of each report and the
MR and/or CT images shown, if any. In addition, the
presence of contrast enhancement, its distribution pattern
(i.e., patchy, punctate, homogeneous, or unknown), and the
dissemination pattern of lesions were listed. With respect to
the latter, we distinguished between unilobar, multilobar
(i.e., two or more contiguous lobes affected), and wide-
spread (i.e., two or more noncontiguous lobes affected and/
or the presence of lesions in both hemispheres). For the
sake of clinical relevance and vigilance, symptoms and
radiological lesions that appeared after establishing the
diagnosis of PML, attributable to either progression of the
disease or a consecutive emerging IRIS, were excluded.
Statistical analysis
Differences between the four subgroups, based on the
underlying disease categories, were analyzed using Chi-
square tests and one-way ANOVA. Post-hoc Bonferroni
corrections have been applied and significance levels were
set at 0.0083 (i.e., 0.05/6). Due to the conservative nature
of the Bonferroni method [11], it seems likely that potential
differences between the subgroups represent genuine dis-
similarities rather than mere coincidence.
Results
Demographic and epidemiologic features
The literature search yielded 287 cases of drug-related PML
in 184 case reports, 21 case series, 18 observational studies,
three experimental studies, and two review articles
[12–239]. Furthermore, an additional 39 reports were iden-
tified in the Dutch pharmacovigilance database, resulting in
a total number of 326 documented cases. In eight cases,
consensus was reached after initial doubt on the diagnosis of
PML; five of them have been included, while the remaining
three were finally labeled as ‘not PML’. Natalizumab,
predniso(lo)ne, (dimethyl) fumarate, fludarabine, rituximab,
and brentuximab vedotin were the most common single
agents that have been demonstrated to trigger PML (Online
Resource 1). Additionally, glucocorticoids with either aza-
thioprine or cyclophosphamide and a regime containing four
or more pharmaceuticals [usually courses of chemotherapy,
frequently including rituximab (R-CHOP)] comprised the
most prevalent composite culprits. The multifarious under-
lying diseases could be subdivided into four main categories,
i.e. multiple sclerosis (MS), (other) immune-mediated dis-
orders, neoplasms (93.8 % lymphoproliferative, 3.1 %
myeloproliferative, 2.1 % solid neoplasm, 1.0 % unknown),
and the post-transplantation setting (Fig. 3). Because of the
relatively large number of natalizumab-associated PML
cases, the former was not included in the group of immune-
mediated diseases, but rather considered a distinct entity. As
immunosuppressive drugs are also frequently used in the
prevention of relapses in neuromyelitis optica spectrum
disorder after a first episode, one might expect drug-asso-
ciated PML to have been described in this patient popula-
tion. However, no such reports have been identified in our
search. The most common drugs associated with PML per
subgroup are summarized in Online Resource 2. In general,
there was considerably few drug overlap between the vari-
ous disease categories, an exception being the combination
of azathioprine and glucocorticoids which was used in both
autoimmune disorders and the post-transplantation setting.
The age and sex distribution of drug-related PML
among the subgroups were in accordance with the epi-
demiologic features of the particular diseases, with a higher
percentage of younger women and older men in the MS
and neoplasm subgroups, respectively (Table 1). The mean
time elapsed from introduction of the drug(s) to first
symptoms was 28.9 (95 % CI 25.5–32.2) months, while the
time span to the occurrence of asymptomatic lesions (only
in natalizumab-induced PML) was found to be 36.4 (95 %
CI 27.0–45.9) months. Significantly shorter periods were
observed in the neoplasm group [mean 14.2 months (95 %
CI 9.3–19.2)] compared to the three other disease cate-
gories (p\ 0.001). A delay of several weeks to even
months between the occurrence of first symptoms and the
final diagnosis of PML was noticed in a considerable
number of cases [23, 28, 50, 67, 78, 101, 103, 117,
122, 149, 158, 185, 201, 213, 223, 224, 226,
233, 235, 236]. This diagnosis was established on com-
bined clinical, radiological, and CSF grounds in 69.4 % of
cases. In the remaining 30.6 %, histopathological analysis
was necessary to provide a greater degree of certainty,
either because PCR for JCV in the CSF was not available
or (repeatedly) negative. Brain biopsies were conducted
most commonly in patients with underlying autoimmune
diseases (43.8 %) and neoplasms (47.8 %), but in only
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8.3 % of natalizumab-induced PML cases. The overall
mortality rate was 52.2 % (95 % CI 46.5–58.0 %), with
values of 12.0 % (95 % CI 5.2–18.7 %), 56.2 % (95 % CI
44.5–67.8 %), 83.3 % (95 % CI 75.5–91.2 %), and 68.4 %
(95 % CI 52.9–83.9 %) in the MS, immune-mediated,
neoplasm and post-transplantation subgroups, respectively.
Clinical characteristics
In descending order of magnitude, the most common
overall symptoms and signs of drug-related PML were
motor weakness (48.6 %), cognitive deficits (43.2 %),
dysarthria (26.3 %), ataxia (24.1 %), aphasia (22.7 %), and
behavioral changes (21.9 %) (Table 2). Although some
deviations were observed between the subgroups, motor
weakness and cognitive changes constituted the two most
frequently encountered symptoms in all disease categories.
Behavioral changes were significantly more common in the
post-transplantation group than in any of the other disease
categories (MS p\ 0.001, immune-mediated disorders
p = 0.001, neoplasms p = 0.002). The highest prevalences
of cognitive deficits and seizures were also found in this
disease category (60.0 and 22.9 %, respectively). Symp-
toms and signs of cerebellar and brainstem involvement,
i.e., ataxia, vertigo, eye movement disorders, and dyspha-
gia tended to be more prevalent in the group of autoim-
mune disorders. Furthermore, dysarthria, gait abnormalities
and sensory deficits (37.3, 26.9, and 20.9 %, respectively)
occurred most commonly in the group of immune-medi-
ated diseases. A notable feature of drug-related PML
Fig. 3 Distribution of cases of drug-associated progressive multifo-
cal leukoencephalopathy among the major disease categories (a) and
subdivisions of the post-transplantation setting (b), the autoimmune
diseases (c), and the neoplasms (d). Because of the large number of
natalizumab-associated PML cases, multiple sclerosis was considered
a distinct entity and was not included in the group of autoimmune
disorders. CML chronic myeloid leukemia, CLL chronic lymphocytic
leukemia, GPA granulomatosis with polyangiitis (formerly Wege-
ner’s disease), MDS myelodysplastic syndrome, NHL non-Hodgkin
lymphoma, NSCLC non-small-cell lung cancer, RA rheumatoid
arthritis, SLE systematic lupus erythematosus, WM Waldenstro¨m’s
macroglobulinemia
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among the neoplasms was the high prevalence of visual
deficits (25.8 %), especially when compared to the
autoimmune disorders (p = 0.001). Asymptomatic PML
cases were only observed in natalizumab-treated patients
(10.3 %).
Radiological findings
Whereas infratentorial lesions were present in 27.4 % of
cases, drug-associated PML was considerably more preva-
lent in the supratentorial brain (87.7 %) (Table 3). In all
disease categories, lesions were most often situated in the
frontal and parietal lobes (64.1 and 46.6 %, respectively).
The temporal (21.4 %) and occipital (22.7 %) lobes were
less commonly affected. Involvement of the latter, however,
was observed relatively frequently in the neoplasm sub-
group (36.2 %), in particular when compared to the
autoimmune and MS groups (p = 0.003 and p = 0.01,
respectively). Infratentorial lesion localization was espe-
cially prevalent in drug-related PML associated with
immune-mediated disorders, with cerebellar involvement
being significantly more common than in the MS and
neoplasm categories (p = 0.001 and p = 0.007, respec-
tively). Furthermore, there was a trend towards a higher
level of brainstem involvement in the group of autoimmune
diseases (MS p = 0.013; neoplasm p = 0.077). In the
natalizumab-induced PML subgroup, lesions were most
commonly distributed in one lobe (42.9 % vs. 21.4 %
multilobar and 27.1 % widespread). In contrast, widespread
dissemination was by far the most frequently encountered
pattern in the remaining three disease categories (autoim-
mune disorders 52.5 %, neoplasms 52.1 %, post-trans-
plantation 68.0 %). Contrast enhancement was present in
27.6 % of cases, particularly in the natalizumab-induced
(42.9 %) and post-transplantation (31.6 %) subgroups. In
the former, punctate and patchy enhancement patterns were
observed to an equal extent (19.6 %). In the other sub-
groups, only patchy contrast enhancement was found.
CSF results
JCV DNA remained (repeatedly) undetectable in 22.7 %
(95 % CI 17.3–28.1 %) of drug-associated PML cases.
Furthermore, nearly one out of each seven patients
(13.7 %; 95 % CI 9.3–18.1 %) initially displayed one or
more negative outcomes before PCR finally converted to
positive, ranging from 4.8 % in the post-transplantation
(95 % CI 0.0–14.7 %) subgroup to 21.1 % (95 % CI
Table 1 Demographic and epidemiologic features of drug-associated progressive multifocal leukoencephalopathy
Multiple sclerosisa Autoimmune diseases Neoplasms Post-transplantation Total
Number of cases 113 78 97 38 326
Literature 89 (31.0) 75 (26.1) 86 (30.0) 37 (12.9) 287
Lareb 24 (61.5) 3 (7.7) 11 (28.2) 1 (2.6) 39
Age (years) 45.0 ± 10.4*# 54.5 ± 14.2* 58.9 ± 12.4#} 49.7 ± 14.3} 52.2 ± 13.7
Sex (% male) 41/111 (36.9)} 27/76 (35.5)*# 57/92 (62.0)*} 25/38 (65.8)# 150/317 (47.3)
Time to PML onset (months) 37.8 ± 17.0# 30.6 ± 20.5* 14.2 ± 21.4*#} 34.9 ± 37.6} 29.5 ± 24.4
To first symptoms 38.0 ± 17.5# 30.6 ± 20.5* 14.2 ± 21.4*#} 34.9 ± 37.6} 28.8 ± 25.3
To ‘‘silent’’ MRI lesionsb 36.4 ± 12.2 N/A N/A N/A 36.4 ± 12.2
Diagnosis (%)
Clinical–MRI–CSF 97/98 (99.0)*#} 42/73 (57.5)* 52/93 (55.9)# 18/37 (48.6)} 209/301 (69.4)
Histopathology 1/98 (1.0)*#} 31/73 (42.5)* 41/93 (44.1)# 19/37 (51.4)} 92/301 (30.6)
PML classification (%)
Possible 11/99 (11.1) 4/76 (5.3) 9/94 (9.6) 3/38 (7.9) 27/307 (8.8)
Probable 12/99 (12.1)*#} 0/76 (0.0)* 1/94 (1.1)# 0/38 (0.0)} 13/307 (4.2)
Definite 75/99 (75.8) 63/76 (82.9) 79/94 (84.0) 28/38 (73.7) 245/307 (79.8)
Unknown 1/99 (1.0)* 9/76 (11.8) 5/94 (5.3) 7/38 (18.4)* 22/307 (7.2)
Mortality rate (%) 11/92 (12.0)*#} 41/73 (56.2)* 75/90 (83.3)# 26/38 (68.4)} 153/293 (52.2)
Time to death (months) 5.2 ± 3.2 7.0 ± 10.4 3.9 ± 4.5 3.4 ± 3.6 4.8 ± 6.7
Categorical data have been displayed as frequency (percentage), continuous data as mean ± standard deviation
# , *, },  significant differences between subgroups (p\ 0.05/6 = 0.0083)
a Because of the large number of natalizumab-associated PML cases, multiple sclerosis was considered a distinct entity and was not included in
the group of autoimmune disorders
b Asymptomatic PML cases were only observed in natalizumab-treated patients
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12.7–29.4 %) in the MS subgroup. Positive results in the
first CSF sample were obtained in 63.5 %. Pleocytosis was
present in 10.9 % of patients, especially in the neoplasm
group (17.1 %).
Discussion
Despite the exponential increase in the number of drug-
associated PML cases throughout the years, a comprehen-
sive, quantitative analysis of its diagnostic characteristics
that also takes into account the differences between the
various underlying disease categories has not been per-
formed thus far. Our study demonstrates that motor
weakness and cognitive deficits are the most common
presenting symptoms in all subgroups. Several
dissimilarities were observed, however, between the dis-
ease categories in the remaining clinical manifestations.
While behavioral and cognitive changes were most
prevalent among the post-transplantation group, cerebellar
and brainstem symptoms occurred most commonly in the
autoimmune category. Visual disturbances appeared most
frequently in drug-related PML associated with neoplasms.
However, a sound explanation for these differences seems
to be missing.
Because of the frequently grim prognosis and lethal
outcomes, it is of paramount importance to consider the
diagnosis of medication-associated PML at an early stage
during treatment with immunosuppressive drugs. The
clinical phenotype in the articles reviewed, however, was
not seldom initially misinterpreted as an exacerbation or
the cerebral manifestations of the underlying disease, i.e.,











Motor weaknessa 34 (39.1) 34 (50.7) 49 (55.1) 18 (51.4) 135 (48.6)
Cognitive deficitsb 30 (34.5) 25 (37.3) 44 (49.4) 21 (60.0) 120 (43.2)
Dysarthria 13 (14.9)* 25 (37.3)* 27 (30.3) 8 (22.9) 73 (26.3)
Ataxia 14 (16.1) 21 (31.3) 23 (25.8) 9 (25.7) 67 (24.1)
Aphasiac 20 (23.0) 19 (28.4) 20 (22.5) 4 (11.4) 63 (22.7)
Behavioral changed 14 (16.1)# 12 (17.9)* 18 (20.2)} 17 (48.6)#*} 61 (21.9)
Gait abnormalities 14 (16.1) 18 (26.9) 13 (14.6) 5 (14.3) 50 (18.0)
Visual deficitse 10 (11.5) 4 (6.0)* 23 (25.8)* 6 (17.1) 43 (15.5)
Sensory deficits 7 (8.0) 14 (20.9)# 5 (5.6)# 6 (17.1) 32 (11.5)
Seizure 9 (10.3) 5 (7.5) 6 (6.7) 8 (22.9) 28 (10.1)
Facial palsy 5 (5.7) 10 (14.9) 6 (6.7) 6 (17.1) 27 (9.7)
Dysphagia 2 (2.3) 8 (11.9) 6 (6.7) 4 (11.4) 20 (7.2)
Apraxia 3 (3.4) 3 (4.5) 11 (12.4) 2 (5.7) 19 (6.8)
Vertigo 4 (4.6) 6 (9.0) 3 (3.4) 3 (8.6) 16 (5.8)
Eye movement
disordersf
2 (2.3) 6 (9.0) 8 (9.0) 0 (0.0) 16 (5.8)
Headache 2 (2.3) 3 (4.5) 3 (3.4) 3 (8.6) 11 (4.0)
Parkinsonismg 1 (1.1) 6 (9.0) 2 (2.2) 2 (5.7) 11 (4.0)
Depression 4 (4.6) 2 (3.0) 1 (1.1) 1 (2.9) 8 (2.9)
Asymptomatic 9 (10.3)*# 0 (0.0)# 0 (0.0)* 0 (0.0) 9 (3.2)
Data have been displayed as frequency (percentage)
Because of the large number of natalizumab-associated PML cases, multiple sclerosis was considered a distinct entity and was not included in the
group of autoimmune disorders
a Monoparesis, hemiparesis, tetraparesis, hemiplegia, and tetraplegia
b Confusion and memory deficits
c True aphasia and word finding difficulties
d Personality changes, apathy, lethargy, and agitation
e Visual field defects and reduced visual acuity
f Ophtalmoparesis, strabismus, and diplopia
g Tremor, bradykinesia, and ‘parkinsonism’
# , *, } significant differences between subgroups (p\ 0.05/6 = 0.0083)
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an MS relapse, neuropsychiatric lupus, or central nervous
system vasculitis [23, 28, 50, 67, 78, 101, 103, 117, 122,
149, 158, 185, 201, 213, 223, 224, 226, 233, 235, 236]. It
was only after further clinical and radiological worsening
upon high doses of immunosuppressive therapies that the
possibility of PML was considered in these cases. Apart
from the intrinsically dismal prognosis of PML, this delay
of several weeks to even months and additional assault on
the immune system certainly may have contributed to the
high mortality rate. Sometimes, acute symptoms and signs
were attributed to cerebral infarctions [21, 38, 109].
Finally, ocular and vestibular symptoms have occasionally
been misjudged as cataract and Meniere’s disease,
respectively [45, 120, 155]. It is possible that PML
symptoms have been misinterpreted in these cases because
of the relatively long interval between drug introduction
and first central nervous system deficits, on average almost
2.5 years.
The differential diagnosis of medication-associated
PML depends on the context in which the specific
immunosuppressive drug is applied. In the post-transplan-
tation setting, it is important to distinguish between drug-
associated PML and PRES, which usually affects the
parieto-occipital lobes and frequently resolves
Table 3 Radiological and cerebrospinal fluid features of drug-associated progressive multifocal leukoencephalopathy
Multiple sclerosisa Autoimmune diseases Neoplasms Post-transplantation Total
Radiological features
Supratentorial 66/72 (91.7) 46/61 (75.4)* 71/76 (93.4)* 24/27 (88.9) 207/236 (87.7)
Frontal lobe 49/69 (71.0) 32/57 (56.1) 43/69 (62.3) 17/25 (68.0) 141/220 (64.1)
Parietal lobe 22/69 (31.9) 31/58 (53.4) 36/69 (52.2) 14/25 (56.0) 103/221 (46.6)
Temporal lobe 9/69 (13.0) 12/57 (21.1) 21/69 (30.4) 5/25 (20.0) 47/220 (21.4)
Occipital lobe 10/69 (14.5)# 9/57 (15.8) 25/69 (36.2)# 6/25 (24.0) 50/220 (22.7)
Basal ganglia 1/69 (1.4) 3/57 (5.3) 3/69 (4.3) 3/25 (12.0) 10/220 (4.5)
Thalamus 3/69 (4.3) 6/58 (10.3) 8/69 (11.6) 3/25 (12.0) 20/221 (9.0)
Capsula interna 3/69 (4.3) 4/59 (6.8) 2/69 (2.9) 3/25 (12.0) 12/222 (5.4)
Corpus callosum 2/69 (2.9) 3/59 (5.1) 6/69 (8.7) 2/25 (8.0) 13/222 (5.9)
Infratentorial 13/69 (18.8)* 25/60 (41.7)* 15/69 (21.7) 8/25 (32.0) 61/223 (27.4)
Cerebellum 8/69 (11.6)* 21/60 (35.0)*# 10/69 (14.5)# 6/25 (24.0) 45/223 (20.2)
Brain stem 7/69 (10.1) 16/59 (27.1) 10/69 (14.5) 5/25 (20.0) 38/222 (17.1)
Lesion distribution
Unilobar 30/70 (42.9)*# 13/59 (22.0) 13/71 (18.3)* 1/25 (4.0)# 57/225 (25.3)
Multilobar 15/70 (21.4) 13/59 (22.0) 17/71 (23.9) 6/25 (24.0) 51/225 (22.7)
Widespread 19/70 (27.1)*#} 31/59 (52.5)* 37/71 (52.1)# 17/25 (68.0)} 104/225 (46.2)
Unknown 6/70 (8.6) 2/59 (3.4) 4/71 (5.6) 1/25 (4.0) 13/225 (5.8)
Contrast enhancement 24/56 (42.9)* 5/43 (11.6)* 10/45 (22.2) 6/19 (31.6) 45/163 (27.6)
Punctate 11/56 (19.6)*# 0/43 (0.0)* 0/45 (0.0)# 0/19 (0.0) 11/163 (6.7)
Patchy 11/56 (19.6) 3/43 (7.0) 8/45 (17.8) 4/19 (21.1) 26/163 (16.0)
Homogeneous 1/56 (1.8) 0/43 (0.0) 0/45 (0.0) 0/19 (0.0) 1/163 (0.6)
Unknown 1/56 (1.8) 2/43 (4.7) 2/45 (4.4) 2/19 (10.5) 7/163 (4.3)
CSF features
PCR JC virus
Negative 11/95 (11.6)# 15/53 (28.3) 21/64 (32.8)# 6/21 (28.6) 53/233 (22.7)
Directly positive 64/95 (67.4) 31/53 (58.5) 39/64 (60.9) 14/21 (66.7) 148/233 (63.5)
Positive after C2 LPs 20/95 (21.1)* 7/53 (13.2) 4/64 (6.3)* 1/21 (4.8) 32/233 (13.7)
Leukocytes/ul
0–4 17/19 (89.5) 38/41 (92.7) 34/41 (82.9) 17/18 (94.4) 106/119 (89.1)
C5 2/19 (10.5) 3/41 (7.3) 7/41 (17.1) 1/18 (5.6) 13/119 (10.9)
Data have been displayed as frequency (percentage)
LP lumbar puncture
*, #, } significant differences between subgroups (p\ 0.05/6 = 0.0083)
a Because of the large number of natalizumab-associated PML cases, multiple sclerosis was considered a distinct entity and was not included in
the group of autoimmune disorders
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spontaneously after withdrawal of the culprit(s). In MS
patients, on the other hand, the distinction between a
relapse and natalizumab-induced PML can be particularly
troublesome. A correct and early diagnosis, however, has
important therapeutic and prognostic implications. In this
regard, several clinical and MRI features may direct the
physician to the right diagnosis. Acute spinal cord or
brainstem presentations and focal, sharp-edged, periven-
tricular locations are generally more frequently encoun-
tered in an MS exacerbation. In contrast, PML is
characterized by a subacute onset, progressive nature of
(sub)cortical symptoms, and large, ill-defined, confluent
T2-weighted lesions, deep gray matter involvement, and/or
crescent cerebellar lesions [240, 241]. This study confirms
these findings, the most common natalizumab-associated
PML symptoms being motor weakness, cognitive deficits,
and aphasia, and lesions mainly localized in the frontal and
parietal lobes. Isolated brainstem involvement, however,
does not exclude PML at all [201, 233]. New imaging
procedures such as the application of susceptibility
weighted imaging and ultra high-field 7 Tesla MRI have
shown promising preliminary data in the distinction
between PML and MS lesions and might finally play a
pivotal role when regular techniques fail to attain full
assurance [242]. However, further work is required before
they can be implemented in everyday clinical practice.
Due to the raised level of radiological vigilance in
natalizumab-treated patients including high-frequency MRI
monitoring according to recent expert opinion guidelines
[243, 244], cases of PML diagnosed at an asymptomatic
stage are identified with increasing frequency
[19, 27, 123, 137, 153, 162, 221]. These cases are only
classified as probable PML in the presence of JCV DNA in
the CSF detected by PCR, indicating the conservative
nature of the current diagnostic criteria [3]. The predica-
ment of negative or inconclusive results across different
laboratories in view of asymptomatic patients displaying
MRI lesions has been touched upon previously [221] and
stresses the need of a revision of the diagnostic PML
criteria.
Definitive establishment of the PML diagnosis was
hampered by initially negative PCR outcomes in CSF
samples in nearly one out of each seven patients before it
finally converted to positive. These results are strongly
dependent on the disease stage and the characteristics of
the assay, especially its lower detection limit, the sensi-
tivity of the older assays being approximately 75 % [3].
Samples were frequently analyzed not only in the insti-
tute’s own laboratory, but also in external facilities, with
the National Institutes of Health laboratory being the one
with the most ultrasensitive assay (i.e., a detection limit of
10 JCV DNA copies per milliliter). Thus, physicians need
to be aware that the lack of detection of JCV DNA in CSF
does not preclude the diagnosis of PML. Repeated lumbar
punctures, follow-up MRI, and possibly additional tech-
niques currently under evaluation such as the assessment of
anti-JCV antibodies in CSF [245], and in a proportion of
cases, biopsy may be required to confirm the diagnosis of
PML.
A clear radiological anterior-posterior gradient was
observed, with the frontal and parietal lobes being more
often involved than their temporal and occipital counter-
parts. A widespread lesion distribution pattern was found to
be most common in drug-related PML associated with
autoimmune disorders, neoplasms, and the post-transplan-
tation setting, while (asymptomatic) unilobar involvement
was most often observed in the natalizumab-induced sub-
group. Contrast enhancement was present in about one
fourth of cases of drug-associated PML, especially in the
MS and post-transplantation subgroups. Although the
underlying mechanisms and evolution of this ‘inflamma-
tory PML’ variant remain to be elucidated, experimental
evidence in natalizumab-induced PML suggests that lym-
phocyte trafficking continues to occur via alternative
pathways due to upregulation of different adhesion mole-
cules, thereby inducing a state of incomplete immune
surveillance [246].
In contrast to what its name may suggest, the thalamus
and basal ganglia—obviously deep gray matter struc-
tures—were involved in the PML disease process in 9.0
and 4.5 % of cases, respectively. Berger et al. previously
demonstrated lesions in these areas in 14 and 12 % in PML
associated with human immunodeficiency virus [247].
Furthermore, seizures which are generally assumed to be
generated by synchronous cortical activity were present in
10.1 % of patients. In previous studies, even higher
prevalences of 18 and 34.7 % were found, with causative
PML lesions being situated adjacent to the T1-hyperintense
cerebral cortical gray matter [248, 249]. It can be inferred
from both observations that the ‘leukoencephalopathy’
phrase in the term PML, suggesting a white matter disease,
is actually kind of a misnomer and rather confusing for
clinicians who are not familiar with this disease.
The discrepancies in survival between the different
categories of PML—not only the drug-associated cases, but
also the ones related to an intrinsically compromised
immune system—can probably be explained by their var-
ious degrees of ‘generalized’ immunosuppression. The
more specific the immune system is targeted, the lower the
mortality rate in general. We demonstrated a significantly
lower mortality rate in the natalizumab-induced PML
subgroup compared to the other disease categories and
found the highest value in the neoplasm subgroup. As
natalizumab impedes the interaction between alpha-4
integrin on lymphocytes and vascular cell adhesion mole-
cule 1 on the endothelium of the vessel wall, it specifically
2012 J Neurol (2016) 263:2004–2021
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prevents the diapedesis of these cells through the blood
brain barrier without reducing the total number of leuko-
cytes in the blood or their function. Therefore, in contrast
to the various antineoplastic agents and immunosuppres-
sive drugs used in cancer and the post-transplantation set-
ting, the immune system may be more specifically
suppressed. Depression of the immune system may not
only result from the drugs administered, but is also an
intrinsic consequence of the disease process in hemato-
logical malignancies which accounts for the highest mor-
tality rate in this subgroup. Furthermore, the high level of
radiological vigilance and occurrence of asymptomatic
PML cases among MS patients treated with natalizumab
frequently led to a quick drug suspension which probably
contributed to a better prognosis.
Several intrinsic limitations of this study need to be
addressed. Although we identified a large number of
reports, not all cases of medication-related PML are pub-
lished in the literature, especially when the association
between the drug and the side effect has been described
before. Therefore, our study design does not allow calcu-
lating the treatment-related risk of developing PML for
each specific drug. Second, the contrast between underre-
porting in the oncology field on the one hand and the high
clinical and radiological vigilance in MS and autoimmune
disorders on the other has possibly led to a skewed distri-
bution of published cases. Furthermore, the causal rela-
tionship between the mentioned drugs and PML may have
been blurred by a variety of reasons. First, a state of
immunosuppression could have already been present as a
result of the underlying disease itself, e.g., due to lym-
phopenia in SLE, sarcoidosis, or leukemia. Indeed, PML
has been described in these disorders in the absence of
immunosuppressive medication [250, 251]. Therefore, it
seems plausible to assume that PML in the group of neo-
plasms and in some but not all autoimmune disorders
results from the interaction and synergistic immunosup-
pressive effects of the given drug(s) and the underlying
disease. In the MS and post-transplantation setting, on the
other hand, PML seems to be entirely attributable to
iatrogenic reasons. Second, it is not inconceivable that
several reports only mentioned the drug(s) that were taken
at the time of PML onset, without giving notice to previous
use of immunosuppressive therapies or long-standing
leukopenia. As a result, the drugs mentioned may just have
given the final push to the diagnosis of PML rather than
being fully responsible. In most cases of this study (277/
326, 85 %), the risk of medication-associated PML seemed
related to a maximum of three drugs. However, in this
respect the heterogeneity of the data set needs to be
appreciated and one should take into account several other
factors like duration of treatment, concomitant medication
use, and comorbidity.
In conclusion, drug-associated PML represents an
emerging yet underrecognized clinical entity. We
demonstrated that the various subgroups share several
clinical and radiological characteristics despite the
highly heterogeneous nature of the underlying diseases.
In all subgroups, motor weakness and cognitive changes
comprised the two most common clinical manifestations,
while the frontal and parietal lobes invariably appeared
to be the predilection sites of PML lesions. Nonetheless,
it is important to be aware of subtle—and sometimes
more obvious—differences in preferential presentations,
e.g., discrepancies in the patterns of lesion dissemination
and contrast enhancement. In the end, meticulous clini-
cal and radiological vigilance in recognizing the phe-
notype at an early stage coupled with prompt withdrawal
and clearance of the culprit, appropriate supportive
therapies, and accurate monitoring and treatment of a
consecutive IRIS remain crucial to obtain better out-
comes in the battle against this frequently relentless
disease.
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